These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15337743)

  • 1. Latency and substrate binding globally reduce solvent accessibility of plasminogen activator inhibitor type 1 (PAI-1). An adaptation of PAI-1 conformer crystal structures by hydrogen-deuterium exchange.
    Nukuna BN; Penn MS; Anderson VE; Hazen SL
    J Biol Chem; 2004 Nov; 279(48):50132-41. PubMed ID: 15337743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein conformational change delayed by steric hindrance from an N-linked glycan.
    Bager R; Johansen JS; Jensen JK; Stensballe A; Jendroszek A; Buxbom L; Sørensen HP; Andreasen PA
    J Mol Biol; 2013 Aug; 425(16):2867-77. PubMed ID: 23702291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.
    Jankun J; Specht Z; Szkudlarek M; Greenfield R; Gaikwad B; Trifonov L; Vaugeois J; Aleem AM; Basrur V; Selman SH; Zavodszky MI; Skrzypczak-Jankun E
    Int J Mol Med; 2006 Mar; 17(3):437-47. PubMed ID: 16465390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.
    Na YR; Im H
    Protein Sci; 2005 Jan; 14(1):55-63. PubMed ID: 15576554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
    Gils A; Declerck PJ
    J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding.
    Verhamme I; Kvassman JO; Day D; Debrock S; Vleugels N; Declerck PJ; Shore JD
    J Biol Chem; 1999 Jun; 274(25):17511-7. PubMed ID: 10364183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin.
    Trelle MB; Hirschberg D; Jansson A; Ploug M; Roepstorff P; Andreasen PA; Jørgensen TJ
    Biochemistry; 2012 Oct; 51(41):8256-66. PubMed ID: 22957734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.
    Hansen M; Busse MN; Andreasen PA
    Eur J Biochem; 2001 Dec; 268(23):6274-83. PubMed ID: 11733024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.
    Kvassman JO; Lawrence DA; Shore JD
    J Biol Chem; 1995 Nov; 270(46):27942-7. PubMed ID: 7499270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.
    D'Amico S; Martial JA; Struman I
    FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C.
    Dupont DM; Blouse GE; Hansen M; Mathiasen L; Kjelgaard S; Jensen JK; Christensen A; Gils A; Declerck PJ; Andreasen PA; Wind T
    J Biol Chem; 2006 Nov; 281(47):36071-81. PubMed ID: 17018527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-range allostery mediates the regulation of plasminogen activator inhibitor-1 by cell adhesion factor vitronectin.
    Kihn K; Marchiori E; Spagnolli G; Boldrini A; Terruzzi L; Lawrence DA; Gershenson A; Faccioli P; Wintrode PL
    J Biol Chem; 2022 Dec; 298(12):102652. PubMed ID: 36444882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.
    Bucci JC; Trelle MB; McClintock CS; Qureshi T; Jørgensen TJ; Peterson CB
    Biochemistry; 2016 Aug; 55(31):4386-98. PubMed ID: 27416303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.